Skip to main content

Silje Watterdal Syversen

Senior researcher
https://orcid.org/0000-0003-2159-3696
See Google Scholar profile
See publications in PubMed

Education

  • Cand.med., University of Oslo (2002)
  • Doctoral degree at the Department of Clinical Medicine, University of Oslo (2010)

Position

  • Senior researcher, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital
  • Senior physician in rheumatology, Clinic for rheumatology, outpatient clinic and research, Diakonhjemmet hospital

Field of interest

  • Rheumatology
  • Rheumatoid arthritis
  • New-onset arthritis
  • Immunosuppressive medications
  • Personalized medicine
  • Therapeutic drug monitoring
  • Immunogenicity
  • Randomized controlled trials
  • Biomarkers
  • Autoantibodies
  • Epidemiology
  • Vaccine response

Other

  • Co-leader of work package 1 in REMEDY (Treatment studies)
  • Head of the Norwegian Rheumatology Association

Email

Telephone

+47 22451500

visiting address

Diakonhjemmet hospital
Forstanderboligen
Reidar Kobros vei 8
0370 Oslo

Postal address

Diakohjemmet hospital
PO Box 23 Vinderen
0319 Oslo

Projects

WP2 - PPhenotyping for personalized medicine

NOR DRUM

The Norwegian study for therapeutic drug monitoring

Project Manager:
Espen A. Haavardsholm
WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive treatment

Project Manager:
Guro Løvik Goll
WP1 - Optimized medical interventions

RA DRUM

Therapeutic drug monitoring in patients with rheumatoid arthritis (RA-DRUM)

Project Manager:
Silje Watterdal Syversen
WP2 - PPhenotyping for personalized medicine

RIMRA

Rheumatic immune-related side effects in patients treated with immunotherapy

Project Manager:
Marte Schrumpf Heiberg
WP1 - Optimized medical interventions

SQUEEZE

Maximizing the effect of prescription drugs in rheumatoid arthritis 

Project Manager:
Espen A. Haavardsholm
WP2 - PPhenotyping for personalized medicine

START

Stratification of acute inflammatory arthritis

Project Manager:
Silje Watterdal Syversen

Publications

Publications taken from the National Science Archive (NVA):

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyzes of the randomised, controlled NOR-DRUM trials

Marthe Kirkesæther Brun, Johanna Gehin, Kristin Reine Hammersbøen, David Warren, Rolf Klaasen, Joseph Sexton


The Lancet Rheumatology

2024

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Hassen Kared, Ingrid Jyssum, Amin Alirezaylavasani, Ingrid Marie Egner, Trung The Tran, Lisa Tietze


Frontiers in Immunology

2024

Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study

Hilde Sofie Sager Ørbo, Kristin Reine Hammersbøen, Joseph Sexton, Ingrid Jyssum, Anne Therese Tveter, Ingrid Egeland Christensen


RMD Open

2024

T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study

Asia-Sophia Fumika Michaela Wolf, Kristin Reine Hammersbøen, Hilde Sofie Sager Ørbo, Sabin Bhandari, Guri Solum, Ingrid Fadum Kjønstad


EBioMedicine

2024

Therapeutic serum level for adalimumab in rheumatoid arthritis: exploratory analyzes of data from a randomized phase III trial

Johanna Gehin, Rolf Klaasen, Eirik Kristianslund, Ingrid Jyssum, Joseph Sexton, David Warren


RMD Open

2024

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases

Ingrid Jyssum, Johanna Gehin, Joseph Sexton, Eirik Kristianslund, Yi Hu, David Warren


Rheumatology

2023

T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis

Asia-Sophia Fumika Michaela Wolf, Anthony Ravussin, Marton König, Mathias Herstad Øverås, Guri Solum, Ingrid Fadum Kjønstad


JCI Insight

2023

HLA-DQ2 is associated with anti-drug antibody formation to infliximab in patients with immune-mediated inflammatory diseases

Marthe Kirkesæther Brun, Kristin Reine Hammersbøen, Marte Kathrine Viken, Grethe-Elisabeth Stenvik, Rolf Klaasen, Johanna Gehin


Journal of Internal Medicine

2023

HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysis

Virginia Solitano, Antonio Facciorusso, Dermot PB McGovern, Tran Nguyen, Ruben J. Colman, Lily Zou


Clinical Gastroenterology and Hepatology

2023

Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type

Kristin Kaasen Jørgensen, Marte Lie Høivik, Adity Chopra, Jurate Saltyte Benth, Petr Ricanek, Bjørn Allan Moum


Scandinavian Journal of Gastroenterology

2023

EULAR points to consider for therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal diseases

Charlotte LM Krieckaert, Astrid Van Tubergen, Johanna Elin Gehin, Borja Hernández-Breijo, Guillaume Le Mélédo, Alejandro Balsa


Annals of the Rheumatic Diseases

2022

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study

Kristin H. Bjørlykke, Hilde Sofie Sager Ørbo, Anne Therese Tveter, Ingrid Jyssum, Joseph Sexton, Trung Tran


The Lancet Rheumatology

2022

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Ingrid Egeland Christensen, Trung Tran


RMD Open

2022

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study

Ingrid Egeland Christensen, Ingrid Jyssum, Anne Therese Tveter, Joseph Sexton, Trung Tran, Siri Mjaaland


BMC Medicine

2022

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine

Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, Meghna Jani, Nils Bolstad, Silje Watterdal Syversen


BioDrugs

2022

Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia

Kristin Reine Hammersbøen, Jørgen Jahnsen, Jørn Brynskov, Pauliina Molander, Michael Eberhardson, Loà G. Davidsdottir


Scandinavian Journal of Gastroenterology

2022

Proactive Therapeutic Drug Monitoring Versus Conventional Management for Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis

Nghia H. Nguyen, Virginia Solitano, Sudheer K. Vuyyuru, John K. MacDonald, Silje Watterdal Syversen, Kristin Kaasen Jørgensen


Gastroenterology

2022

Risk factors for anti-drug antibody formation to infliximab: Secondary analyzes of a randomized controlled trial

Marthe Kirkesæther Brun, Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Johanna Elin Gehin, Øystein Sandanger


Journal of Internal Medicine

2022

Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy

Silje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, Trung Tran, Joseph Sexton, Sella Aarrestad Provan


Arthritis & Rheumatology

2022

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum, Hassen Kared, Trung Tran, Anne Therese Tveter, Sella Aarrestad Provan, Joseph Sexton


The Lancet Rheumatology

2021

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.

Johanna Elin Gehin, Silje Watterdal Syversen, David Warren, Guro Løvik Goll, Joseph Sexton, Nils Bolstad


RMD Open

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Silje Watterdal Syversen, Kristin Kaasen Jørgensen, Guro Løvik Goll, Marthe Kirkesæther Brun, Øystein Sandanger, Kristin Reine Hammersbøen


Journal of the American Medical Association (JAMA)

2021

Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study

Johanna Elin Gehin, David Warren, Silje Watterdal Syversen, Elisabeth Lie, Joseph Sexton, Liz Paucar Loli


Scandinavian Journal of Rheumatology

2021

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort

Johanna Elin Gehin, Rolf Klaasen, ELLEN SAUAR NORLI, David Warren, Silje Watterdal Syversen, Guro Løvik Goll


Rheumatology International

2021

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Øystein Sandanger, Joseph Sexton, Inge Christoffer Olsen


Journal of the American Medical Association (JAMA)

2021

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (The NOR-DRUM study)

Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Øystein Sandanger, Johanna Elin Gehin


Trials

2020

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study

Johanna Elin Gehin, Guro Løvik Goll, David John Warren, Silje Watterdal Syversen, Joseph Sexton, Eldri Kveine Strand


Arthritis Research & Therapy

2019

Associations between cytokine levels and CYP3A4 phenotype in patients with rheumatoid arthritis

Birgit Malene Tovik Wollmann, Silje Watterdal Syversen, Maria Vistnes, Elisabeth Lie, Lise Larsen Mehus, Espen Molden


Drug Metabolism And Disposition

2018

4β-hydroxycholesterol level in patients with rheumatoid arthritis before vs. after initiation of bDMARDs and correlation with inflammatory state

Birgit Malene Tovik Wollmann, Silje Watterdal Syversen, Elisabeth Lie, Caroline Gjestad, Lise Larsen Mehus, Inge Christoffer Olsen


Clinical and Translational Science (CTS)

2017

Dickkopf-1 is associated with periarticular bone loss in patients with rheumatoid arthritis

Berit Helen Jensen Grandaunet, Silje Watterdal Syversen, Mari Hoff, Glenn Haugeberg, Désirée Van der Hejde, Tore Kristian Kvien


Open Journal of Rheumatology and Autoimmune Diseases

2013

FCRL3-169C/C Genotype Is Associated with Anti-citrullinated Protein Antibody-positive Rheumatoid Arthritis and with Radiographic Progression

Marthe Thoresen Mæhlen, Gry Beate Namløs Nordang, Silje Watterdal Syversen, Desirée van der Heijde, Tore Kristian Kvien, Till Uhlig


Journal of Rheumatology

2011

Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis

Hans Ulrich Scherer, Diane van der Woude, Annemiek Willemze, Leendert A. Trouw, Rachel Knevel, Silje Watterdal Syversen


Annals of the Rheumatic Diseases

2011

Association Between High Plasma Levels of Hepatocyte Growth Factor and Progression of Radiographic Damage in the Joints of Patients With Rheumatoid Arthritis

Berit Helen Grandaunet, Silje Watterdal Syversen, Mari Hoff, Anders Sundan, Glenn Haugeberg, Desiree van der Heijde


Arthritis and Rheumatism

2011

The ACPA isotype profile reflects long-term radiographic progression in rheumatoid arthritis

Diane van der Woude, Silje Watterdal Syversen, Ellen IH van der Voort, Kirsten N. Verpoort, Michael PM van der Linden, Annette HM van der Helm-van Mil


Annals of the Rheumatic Diseases

2010

Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs

Silje Watterdal Syversen, Espen A. Haavardsholm, Pernille Helen Bøyesen, Guro Løvik, Per Ivar Brachel Gaarder, Désirée van der Heijde


Annals of the Rheumatic Diseases

2010

Prediction of radiographic progression in rheumatoid arthritis and the role of antibodies against mutated citrullinated vimentin: results from a 10-year prospective study

Silje Watterdal Syversen, D van der Heijde, Robert Landewé, Benedicte Alexandra Lie, Sigrid Ødegård, Till Uhlig


Annals of the Rheumatic Diseases

2010

Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis

Sigrid Ødegård, Silje Watterdal Syversen, Robert Landewé, D van der Heijde, T Uhlig, P Mowinckel


Annals of the Rheumatic Diseases

2010

Antibodies to cyclic citrullinated protein and erythrocyte sedimentation rate predict hand bone loss in patients with rheumatoid arthritis of short duration: a longitudinal study

Pernille Helen Bøyesen, Mari Hoff, Sigrid Ødegård, Glenn Haugeberg, Silje Watterdal Syversen, Per Ivar Brachel Gaarder


Arthritis Research & Therapy

2009

Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic Progression

Silje Watterdal Syversen, GL Goll, D van der Heijde, R Landewe, Per Ivar Brachel Gaarder, Sigrid Ødegård


Journal of Rheumatology

2009

Cortical hand bone loss after 1 year in early rheumatoid arthritis predicts radiographic hand joint damage at 5-year and 10-year follow-up

Mari Hoff, Glenn Haugeberg, Sigrid Ødegård, S Syversen, R Landewe, D van der Heijde


Annals of the Rheumatic Diseases

2009

Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria

WP Maksymowych, R Landewe, PP Tak, CJ Ritchlin, M Ostergaard, PJ Mease


Journal of Rheumatology

2009

Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design

WP Maksymowych, O Fitzgerald, GA Wells, DD Gladman, R Landewe, M Ostergaard


Journal of Rheumatology

2009

Testing of the OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage in Rheumatoid Arthritis: A Systematic Literature Search on 5 Candidate Biomarkers

Silje Watterdal Syversen, R Landewe, D van der Heijde, JM Bathon, M Boers, VP Bykerk


Journal of Rheumatology

2009

High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study

Silje Watterdal Syversen, PI Gaarder, GL Goll, S Odegard, EA Haavardsholm, P Mowinckel


Annals of the Rheumatic Diseases

2008

A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients

Silje Watterdal Syversen, GL Goll, Espen A. Haavardsholm, Pernille Helen Bøyesen, T Lea, Tore Kristian Kvien


Arthritis Research & Therapy

2008